Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences cash
Cash and short-term investments held at the end of each period.
Maravai LifeSciences's cash was $70.09M at Jun 30, 2026. For fiscal 2025 it was $216.89M, down 32.7% from the year before. The highest annual figure on record is $632.14M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.89M | -32.7% |
| FY2024 | Dec 31, 2024 | $322.40M | -43.9% |
| FY2023 | Dec 31, 2023 | $574.96M | -9.0% |
| FY2022 | Dec 31, 2022 | $632.14M | +14.7% |
| FY2021 | Dec 31, 2021 | $551.27M | +133.4% |
| FY2020 | Dec 31, 2020 | $236.18M | +856.2% |
| FY2019 | Dec 31, 2019 | $24.70M | +13.0% |
| FY2018 | Dec 31, 2018 | $21.87M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $70.09M | -74.0% |
| Q1 FY2026 | Mar 31, 2026 | $165.92M | -41.8% |
| Q4 FY2025 | Dec 31, 2025 | $216.89M | -32.7% |
| Q3 FY2025 | Sep 30, 2025 | $243.57M | -57.9% |
| Q2 FY2025 | Jun 30, 2025 | $269.91M | -52.9% |
| Q1 FY2025 | Mar 31, 2025 | $285.05M | -49.3% |
| Q4 FY2024 | Dec 31, 2024 | $322.40M | -43.9% |
| Q3 FY2024 | Sep 30, 2024 | $578.16M | -0.2% |
| Q2 FY2024 | Jun 30, 2024 | $573.17M | -1.2% |
| Q1 FY2024 | Mar 31, 2024 | $561.69M | -10.6% |
| Q4 FY2023 | Dec 31, 2023 | $574.96M | -9.0% |
| Q3 FY2023 | Sep 30, 2023 | $579.61M | -6.1% |
| Q2 FY2023 | Jun 30, 2023 | $580.18M | +5.4% |
| Q1 FY2023 | Mar 31, 2023 | $628.27M | +45.6% |
| Q4 FY2022 | Dec 31, 2022 | $632.14M | +14.7% |
| Q3 FY2022 | Sep 30, 2022 | $617.45M | +12.7% |
| Q2 FY2022 | Jun 30, 2022 | $550.68M | +47.0% |
| Q1 FY2022 | Mar 31, 2022 | $431.47M | +74.2% |
| Q4 FY2021 | Dec 31, 2021 | $551.27M | +133.4% |
| Q3 FY2021 | Sep 30, 2021 | $547.90M | +338.7% |
| Q2 FY2021 | Jun 30, 2021 | $374.71M | +343.7% |
| Q1 FY2021 | Mar 31, 2021 | $247.68M | +222.7% |
| Q4 FY2020 | Dec 31, 2020 | $236.18M | +856.2% |
| Q3 FY2020 | Sep 30, 2020 | $124.88M | +471.1% |
| Q2 FY2020 | Jun 30, 2020 | $84.46M | – |
| Q1 FY2020 | Mar 31, 2020 | $76.75M | – |
| Q4 FY2019 | Dec 31, 2019 | $24.70M | – |
| Q4 FY2018 | Dec 31, 2018 | $21.87M | – |
See a number that looks wrong?